BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25709040)

  • 1. Fragment-based design of kinase inhibitors: a practical guide.
    Erickson JA
    Methods Mol Biol; 2015; 1289():157-83. PubMed ID: 25709040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of fragments for kinase inhibitor design: decoration is key.
    Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
    J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
    van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
    Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual fragment preparation for computational fragment-based drug design.
    Ludington JL
    Methods Mol Biol; 2015; 1289():31-41. PubMed ID: 25709031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-based discovery of JAK-2 inhibitors.
    Antonysamy S; Hirst G; Park F; Sprengeler P; Stappenbeck F; Steensma R; Wilson M; Wong M
    Bioorg Med Chem Lett; 2009 Jan; 19(1):279-82. PubMed ID: 19019674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment-based approaches to the discovery of kinase inhibitors.
    Mortenson PN; Berdini V; O'Reilly M
    Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment library design: using cheminformatics and expert chemists to fill gaps in existing fragment libraries.
    Kutchukian PS; So SS; Fischer C; Waller CL
    Methods Mol Biol; 2015; 1289():43-53. PubMed ID: 25709032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors.
    Wang YS; Strickland C; Voigt JH; Kennedy ME; Beyer BM; Senior MM; Smith EM; Nechuta TL; Madison VS; Czarniecki M; McKittrick BA; Stamford AW; Parker EM; Hunter JC; Greenlee WJ; Wyss DF
    J Med Chem; 2010 Feb; 53(3):942-50. PubMed ID: 20043700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
    Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
    J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing an orally available nontoxic p38 inhibitor with a fragment-based strategy.
    Guarnieri F
    Methods Mol Biol; 2015; 1289():211-26. PubMed ID: 25709042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-based approaches and computer-aided drug discovery.
    Rognan D
    Top Curr Chem; 2012; 317():201-22. PubMed ID: 21710380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational methods for fragment-based ligand design: growing and linking.
    Bienstock RJ
    Methods Mol Biol; 2015; 1289():119-35. PubMed ID: 25709037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel strategy for three-dimensional fragment-based lead discovery.
    Yuan H; Lu T; Ran T; Liu H; Lu S; Tai W; Leng Y; Zhang W; Wang J; Chen Y
    J Chem Inf Model; 2011 Apr; 51(4):959-74. PubMed ID: 21438547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based discovery of focal adhesion kinase inhibitors.
    Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Free-Wilson selectivity analysis for combinatorial library design.
    Sciabola S; Stanton RV; Johnson TL; Xi H
    Methods Mol Biol; 2011; 685():91-109. PubMed ID: 20981520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
    Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
    Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.